Showing results (141-150 of 223) with videos related to

Sort By:
Pageof 23
Plos One|September 6, 2007
The N-Myc down regulated Gene1 (NDRG1) Is a Rab4a effector involved in vesicular recycling of E-cadherinSushant K Kachhap, Dennis Faith, David Z Qian, et al.
Anti-Cancer Drugs|June 22, 2007
Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicityRavibhushan Singh, Jeff L Browning, Ralph Abi-Habib, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|October 31, 2022
Outcomes and antibiotic use in patients with coronavirus disease 2019 (COVID-19) admitted to an intensive care unitMegan M Petteys, Leigh Ann Medaris, Julie E Williamson, et al.
Cancer Research|September 23, 2003
CEP-701 and CEP-751 inhibit constitutively activated RET tyrosine kinase activity and block medullary thyroid carcinoma cell growthChristopher J Strock, Jong-In Park, Mark Rosen, et al.
Cancer Prevention Research (Philadelphia, Pa.)|June 20, 2023
Liver Fibrosis Scores and Prostate Cancer Risk and Mortality in the Atherosclerosis Risk in Communities StudyAnqi Wang, Mariana Lazo, Jiayun Lu, et al.
The Prostate|September 2, 2014
Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancerRosa Nadal, Zhe Zhang, Hibba Rahman, et al.
Cancer Biology & Therapy|September 6, 2007
Preclinical and clinical studies with the multi-kinase inhibitor CEP-701 as treatment for prostate cancer demonstrate the inadequacy of PSA response as a primary endpointConnie Collins, Michael A Carducci, Mario A Eisenberger, et al.
Scientific Reports|July 22, 2021
Targeted delivery of cytotoxic proteins to prostate cancer via conjugation to small molecule urea-based PSMA inhibitorsO C Rogers, D M Rosen, L Antony, et al.
Steroids|July 29, 2014
Targeting thapsigargin towards tumorsNhu Thi Quynh Doan, Eleonora Sandholdt Paulsen, Pankaj Sehgal, et al.
Investigational New Drugs|January 19, 2011
Synthesis and cytotoxic activities of some 2-arylnaphtho[2,3-d]oxazole-4,9-dione derivatives on androgen-dependent (LNCaP) and androgen-independent (PC3) human prostate cancer cell linesYakini Brandy, Innocent Ononiwu, Dolapo Adedeji, et al.
Pageof 23